Agilent Board Authorizes Share Repurchase Program, Dividend | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies today said that its board of directors has authorized a new share repurchase program, which will become effective following the completion of its existing $1 billion share repurchase program.

The firm didn't say how much it expects to spend on the new repurchase program but stated that the goal is to "reduce or eliminate dilution resulting from issuances of stock under the company's employee equity incentive programs to maintain a share count of approximately 335 million diluted shares."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.